Medically reviewed by Austin Baraki, MD | Reviewed quarterly
Two-thirds. That is approximately how much of the weight people regain within a year of stopping semaglutide, based on the STEP 1 trial extension.¹ The trial had produced an average weight loss of about 17% of body weight over 68 weeks. One year after the last injection, about two-thirds of the weight had returned. Improvements in blood pressure, fasting glucose, HbA1c, and lipid numbers drifted backwards too.
That number has driven a lot of coverage, perhaps driving people to avoid starting a medication that works, or to stop one that is working, because they assume the weight will “come right back.” Before drawing that conclusion, consider what the withdrawal trials actually showed, what happens when people stop other weight-loss interventions, and what the two-thirds number does and does not tell you.
The Short Answer
Most people regain a significant portion of the weight they lose after stopping GLP-1 medications. This does not mean the treatment “failed”—it reflects how the underlying biology of weight regulation behaves once the intervention is removed.
What do the withdrawal trials actually show?
Three randomized trials have tested what happens when GLP-1 therapy stops. All three converge on the same finding: the drugs work for as long as you take them, and they do not build in a durable reset that persists once you stop.
Important: GLP-1 medications do not produce a permanent reset of body weight regulation. Their effects persist only while the medication is active.
The STEP 1 trial extension followed a subset of the original participants for a year after they stopped semaglutide.¹ During the 68-week treatment phase, the semaglutide group lost about 17% of body weight on average. Over the year after withdrawal, they regained about two-thirds of that loss. The final weight at the one-year follow-up averaged about 5 to 6 percentage points below their baseline. The improvements in cardiometabolic markers were not gone, but most of them were smaller.
The SURMOUNT-4 trial asked the same question for tirzepatide.² All participants first lost weight on tirzepatide for 36 weeks, averaging a 21% reduction in body weight. They were then randomized either to continue tirzepatide or to switch to placebo for another year. The continuation group kept losing, ending at roughly 25% total weight loss. The placebo group regained about 14% of their body weight, landing close to 10% below their original starting weight. Same people, same counseling, same lifestyle support. The only variable that changed was whether the drug was still on board.
STEP 4 tested the question from the other direction.³ People lost weight on semaglutide for 20 weeks, then were randomized to continue or switch to placebo. The continuation group lost an additional 7.9% over the next 48 weeks, whereas the placebo group regained 6.9%. Continuing the medication produces additional weight loss. Withdrawal drives regain.
Table 1. GLP-1 withdrawal trial comparison.
| STEP 1 extension | SURMOUNT-4 | STEP 4 | |
|---|---|---|---|
| Drug | Semaglutide | Tirzepatide | Semaglutide |
| Active phase | 68 weeks | 36 weeks | 20 weeks |
| Weight loss on drug | ~17% | ~21% | ~10.6% |
| Off-drug period | ~52 weeks | ~52 weeks | ~48 weeks |
| Regain off drug | ~two-thirds of loss | ~half of loss | Regained 6.9% |
| Continuation arm | N/A (all stopped) | Kept losing to ~25% | Lost additional 7.9% |
What about the “4x faster regain” headline?
A 2026 systematic review sparked the headline that weight regain after GLP-1s was roughly four times faster than after lifestyle intervention.⁸ That comparison is mathematically true in absolute weight regain per month, but it is driven almost entirely by the fact that the peak losses on GLP-1s are much larger than what lifestyle alone produces. The medications groups lost three to four times more weight, and they regained weight at roughly three to four times the rate. The proportions are similar. The regain curve after GLP-1 withdrawal looks a lot like what intensive lifestyle studies show, scaled up.
Key point: Faster regain after GLP-1s reflects the larger initial weight loss, not a fundamentally different biological response. The proportional pattern of regain is similar to other weight-loss interventions.
Does lifestyle intervention hold the weight off any better?
Lifestyle change alone produces modest weight loss and then fails to hold for most people, even when the program, the coaching, and the personal efforts persist.
The Diabetes Prevention Program randomized 3,234 adults with overweight or obesity and impaired glucose tolerance to metformin, placebo, or intensive lifestyle. At twelve months, nearly two-thirds of the lifestyle group had lost at least 5% of their body weight. By the ten-year follow-up, more than half of that weight was regained despite ongoing program engagement.⁹
Look AHEAD enrolled 5,145 adults with overweight or obesity and type 2 diabetes into an intensive lifestyle intervention that continued for years. The group averaged an 8.6% loss and 68% hit the 5% threshold at one year. By year four, fewer than half of those who achieved clinically significant loss had maintained it.¹⁰
The POUNDS Lost trial ran 811 adults through four different macronutrient patterns at a 750-Calorie-per-day deficit. The specific diet did not matter. Only 15% of participants lost 10% or more of their body weight.¹¹ For comparison, STEP 1 hit 69% at the 10% threshold. SURMOUNT-1 hit 83% on 15 mg tirzepatide.¹,¹²
A meta-analysis of 29 U.S.-based lifestyle trials with professional intervention and at least two years of follow-up found that more than half of the lost weight was regained within two years. By five years, more than 80% was regained, with average sustained loss settling around 3%.¹³
The pattern is consistent across decades of research. About half of people achieve clinically significant weight loss in year one. Roughly one in four hits 10%. Few do better than 15%. Five years out, about one in ten is still holding a clinically meaningful result. The other nine have drifted back toward baseline.
Context: Weight regain is not unique to GLP-1 medications. Long-term data from lifestyle interventions show similar patterns of partial or substantial regain over time.
Compare that to semaglutide, where about 86% of STEP 1 participants achieved at least 5% weight loss, or tirzepatide, where average total weight loss on SURMOUNT-1 approached 21%.1,12 These are not equivalent interventions. The effect size differs by roughly an order of magnitude.
Regain after discontinuation is not a failure of the drug or willpower. It is the same underlying disease reasserting itself, the way it does with lifestyle alone, even if people continue “doing” the lifestyle.
Why does the weight come back?
Weight regain happens after every form of weight loss.4 With medications and surgery, it happens when the intervention stops. With diet and exercise, it happens even when the intervention continues, because the body’s compensatory responses gradually neutralize the deficit the person is maintaining. The direction is the same, but the reason differs.
The dual intervention point model
One model that helps explain this pattern is the dual intervention point framework.¹⁴ In this model, the body has upper and lower boundaries for weight that it defends against crossing, but does comparatively little regulating between those two limits. The lower boundary defends against starvation and is relatively consistent from person to person, mediated in part by leptin signaling from fat tissue. The upper boundary is more variable and, historically, was thought to defend against becoming too heavy to successfully reproduce or escape predators.
The modern food environment has effectively removed the predation pressure. Cheap, energy-dense, engineered food is available on demand. For individuals whose genetics set a higher upper boundary, the food environment produces predictable results: weight gain into overweight and obesity without a strong counter-signal to stop it.
GLP-1 medications work, at least in part, by making the modern food environment less of a trap. The drug reduces appetite, slows gastric emptying, and changes the reward signaling around food. While the drug is on board, making the dietary changes they want to make feels manageable. When the drug comes out of the system over the weeks following the last injection, those signals return to roughly where they were before treatment started. The food environment has not changed. The biology has not changed. The thing that was managing the interaction between the two is gone.
This model is a framework, not a proven mechanism, and the specifics of how the upper boundary is regulated are still being worked out. Multiple candidate signals have been proposed, including hormonal feedback from fat tissue, bone-derived signals related to mechanical loading, and protein-status sensing. The model is useful because it explains why regain happens without invoking willpower, and why some individuals regain more than others: their upper intervention points differ.
If you regain weight after stopping a GLP-1, you have not failed. You have responded the way almost everyone responds when an effective treatment for a chronic condition is discontinued.
What comes back first: fat, muscle, or both?
After weight loss, the regained weight is predominantly fat. This is consistent across the human weight-loss literature.15 People who stop a GLP-1 and regain weight, just like those who stop eating a Calorie deficit, are regaining predominantly fat mass, not muscle.
There is no published trial showing that post-GLP-1 body composition is worse than pre-treatment. The “skinny fat after Ozempic” narrative is popular online and implies that GLP-1s cause disproportionate amounts of muscle loss, but that is not what the published body-composition data show.
The one high-quality MRI dataset available, the SURPASS-3 MRI substudy, showed that tirzepatide reduced intramuscular fat more than it reduced muscle volume.¹⁶ This intramuscular fat, like the metabolically harmful fat in the liver, gets counted as lean mass on body composition scans (DXA), thereby inflating the number. The truth is, lean mass losses on GLP-1s are similar to, if not proportionally less than diet-only weight loss.
The resulting muscle also tends to function better as compared to pre-treatment: less fat between and inside the fibers, stronger per unit of cross-sectional area, and better at handling glucose. From a muscle-quality standpoint, people with obesity often come out of a GLP-1 course with better muscle than they went in with, not worse. For a full treatment of the muscle loss question, measurement limitations, and what training does during treatment, see our full article on GLP-1s and muscle loss.
This finding isn’t meant to suggest that resistance training shouldn’t be a priority for everyone, especially those who are actively losing weight. It is. Training during a weight-loss phase improves body-composition outcomes whether the deficit comes from a drug or a diet. The argument is against using the regain conversation to scare people out of taking a medication that works.
Can you prevent the regain?
Three strategies have evidence behind them for preventing weight regain. None are magic, and the first one is the most effective by a wide margin.
1.Stay on the drug
This is the finding that the continuation trials keep reinforcing. People who stay on GLP-1 therapy keep their weight off. People who stop regain. While there may be some long-lasting weight loss from GLP-1s, these drugs are long-term obesity medications for most patients, the same way a blood pressure medication is long-term. The framing of “getting off” the drug on a fixed timeline is a holdover from how people used to think about short-term weight-loss interventions, as well as the stigmatization of obesity itself, where it’s considered a cosmetic issue instead of a disease. These narratives do not match what the long-term outcomes data show.²,³
For some patients, a lower-dose maintenance approach (stepping down from the peak dose to a lower one once a target weight is reached) is a reasonable middle ground. This is a decision to make with your prescriber based on insurance coverage, side effects, and treatment goals.
2. Resistance training and a protein target
Resistance training plus a protein target in the range of 1.2 to 1.6 g/kg of body weight per day is the best-supported non-pharmacologic intervention for protecting body composition during any weight-loss phase, including one driven by a GLP-1.5,17,18 While the evidence is strongest for preserving lean mass during Caloric restriction from lifestyle interventions, preliminary data from the T-REX trial, which combined a GLP-1 with structured resistance training, suggests training cuts fat-free mass loss roughly in half compared with medication alone.¹⁹ For details on training programming, protein targets, and monitoring, see our full article on GLP-1s and muscle loss.
Our Beginner Template is designed for people new to lifting, and the accompanying article includes all the background information and a free 4-week program.
3. Use the treatment window to build what you can
Similar to continued exercise participation, the best plan for most people with obesity is to stay on some form of GLP-1 therapy long-term, potentially at a lower maintenance dose or reduced frequency once a target is reached. If you do need to come off for reasons of cost, insurance, side effects, or planned pregnancy, the treatment window is still worth something.
Use it to change the parts of your food environment that are changeable: what is in your kitchen, what your workday meals look like, where and how you eat when you are busy, and how much exposure you have to ultra-processed foods (including food delivery apps). Get your training consistent. Get your sleep stable. Those changes are worth making whether or not you ever come off the medication, and they help if you do.
A systematic review found that without a structured behavioral program, weight regain after GLP-1 discontinuation was 6.7 kg greater than when behavioral support was layered in.7 The behavioral piece is doing work even while the drug is on board, and it keeps doing work after the drug comes off.
Should you plan to stay on a GLP-1 indefinitely?
For most patients with obesity, the answer is some form of continued treatment. Obesity is a chronic condition. The same logic that keeps a patient with hypertension on blood pressure medication long-term applies here. The drug is addressing something the food environment and a person’s genetics produce continuously, and stopping it means the underlying problem reasserts itself.
The conversation with your prescriber typically covers three things: whether you can step down from the peak dose to a lower maintenance dose once you have reached a target weight, whether you can extend the injection interval (for example, moving from weekly to every other week for patients who are stable on therapy), and how to handle planned interruptions for reasons like pregnancy or surgery. None of this is a protocol that can be prescribed in an article, but it is the set of levers that has replaced the older “how do I get off this drug” conversation in obesity medicine.
The full picture
GLP-1 medications work while you take them. When you stop, most of the weight comes back, the same way it does when you stop any effective weight-loss intervention. The regain is mostly fat, not muscle. Post-treatment body composition is not worse than pre-treatment. The rate of regain looks dramatic in absolute terms because the drugs produce dramatically more weight loss than lifestyle alone.
Coming off a GLP-1 is not the treatment goal. For most people with obesity, long-term therapy, often at a lower maintenance dose or reduced frequency, is the more realistic plan. Resistance training and a protein target make that plan work better. If you do come off, the treatment window was the window to build the habits that give you the best chance of holding onto what you gained.
The medication handles the deficit. Training handles the muscle. The habits handle the transition.
Should you get a coach?
Coaching can be helpful for many, though individuals on GLP-1s specifically may benefit from the guidance of an exercise and nutrition professional.
Barbell Medicine Coaching pairs you with a physician-led team that can coordinate with your prescriber, design your training, and help you build the food and lifestyle infrastructure that lasts whether you stay on the medication or come off. It is the fastest way to get the training, nutrition, and transition planning handled in one place.If you want the training side handled on your own, our Beginner Template is the starting point. Whey Rx makes the daily protein target easier to hit on a suppressed appetite.
Frequently Asked Questions
How much weight will I regain if I stop?
On average, roughly half to two-thirds of whatever you lost within the first year after stopping, with a wide range of individual variation. People who continue resistance training and a protein target may land at the lower end. People who stop all structure tend to land at the higher end.
The durability of weight loss after GLP-1 cessation is unknown, though existing data sets have not shown that all of the weight is regained. Time will tell with longer follow up.
How fast does the regain happen?
Appetite often comes back within the first week or two after stopping GLP-1s. Measurable weight regain typically becomes obvious in the second month, and the bulk of it shows up over months three through twelve. It is a gradual drift, not a sudden rebound.
Does tapering the dose before stopping help?
There is no published evidence that a specific taper protocol prevents regain compared with stopping. What does work is stepping down to a lower maintenance dose and staying on it instead of stopping entirely. That is a different question from tapering before discontinuation.
Is the regain all water weight?
No. The initial few pounds may be water and glycogen refilling, especially in the first two weeks, but the sustained regain after stopping GLP-1s over the following months is mostly fat tissue. The same relationship is seen in weight regain after lifestyle-only (diet and exercise) weight loss.
Will my body composition be worse than before I started?
Probably not. There is no published trial showing post-GLP-1 body composition is worse than pre-treatment. The regained tissue is predominantly fat. The SURPASS-3 MRI data suggest muscle quality actually improves during treatment because of reduced intramuscular fat. Resistance training during treatment improves outcomes further.
Is there any way to make the results permanent without staying on?
For most people with obesity, the realistic expectation should be long-term therapy. A small subset of patients do well after discontinuing, typically those who used the treatment window to rebuild food environment and training habits and who continued to invest in both after stopping. Discussing step-downs in dose or frequency with your prescriber is a more useful conversation than trying to plan a full off-ramp.
Does tirzepatide cause more regain than semaglutide?
In absolute terms, partly, because there is more to lose back from. In proportional terms (percentage of lost weight that returns within a year), the two drugs look similar. The SURMOUNT-4 placebo group regained roughly half of their loss. The STEP 1 extension group regained roughly two-thirds. The difference is probably explained by trial design and population more than by the molecules themselves.
Further Reading
For more on long-term weight management, muscle retention, and training during GLP-1 therapy:
-
GLP-1s and Muscle Loss: What the Evidence Shows
The full guide to body composition and training considerations on a GLP-1. -
Creatine on Ozempic: Does It Prevent Muscle Loss?
Where creatine fits among resistance training, protein, and muscle-preservation priorities on a GLP-1. -
Protein Recommendations
How to maintain muscle and hit your targets during weight loss. -
Starting Resistance Training
A practical starting point for building strength and preserving muscle.
References
1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725
2. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945
3. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. https://doi.org/10.1001/jama.2021.3224
4. MacLean PS, Bergouignan A, Cornier MA, Jackman MR. Biology’s response to dieting: the impetus for weight regain. Am J Physiol Regul Integr Comp Physiol. 2011;301(3):R581-R600. https://doi.org/10.1152/ajpregu.00755.2010
5. Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376(20):1943-1955. doi:10.1056/NEJMoa1616338
6. Weiss EP, Jordan RC, Frese EM, et al. Effects of weight loss on lean mass, strength, bone, and aerobic capacity. Med Sci Sports Exerc. 2017;49(1):206-217. https://doi.org/10.1249/MSS.0000000000001074
7. West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. doi:10.1136/bmj-2025-085304
8. Deng M, Tian R, Wu C, et al. Weight regain after discontinuation of weight-loss pharmacotherapy: a systematic review and meta-analysis. Lancet eClinicalMedicine. 2026. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00043-X/fulltext
9. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-1686. https://doi.org/10.1016/S0140-6736(09)61457-4
10. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity. 2014;22(1):5-13. https://doi.org/10.1002/oby.20662
11. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859-873. https://doi.org/10.1056/NEJMoa0804748
12. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038
13. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107(10):1755-1767. https://doi.org/10.1016/j.jada.2007.07.017
14. Speakman JR. A nonadaptive scenario explaining the genetic predisposition to obesity: the “predation release” hypothesis. Cell Metab. 2007;6(1):5-12. https://doi.org/10.1016/j.cmet.2007.06.004
15. Dulloo AG, Jacquet J, Girardier L. Autoregulation of body composition during weight recovery in humans: the Minnesota Experiment revisited. Int J Obes. 1996;20(5):393-405.
16. Gastaldelli A, Cusi K, Fernandez Lando L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue (SURPASS-3 MRI). Lancet Diabetes Endocrinol. 2022;10(6):393-406. https://doi.org/10.1016/S2213-8587(22)00070-5
17. Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains. Br J Sports Med. 2018;52(6):376-384. https://doi.org/10.1136/bjsports-2017-097608
18. Sardeli AV, Komatsu TR, Mori MA, et al. Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals. Nutrients. 2018;10(4):423. https://doi.org/10.3390/nu1004042319. T-REX trial: GLP-1 agonist with structured resistance training. Pre-registration and design details on clinical trial registry. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385806
About the Authors
Jordan Feigenbaum, MD
Jordan Feigenbaum, Founder of Barbell Medicine, has an academic background including a Bachelor of Science in Biology, Master of Science in Anatomy and Physiology, and Doctor of Medicine. He holds accreditations from the American College of Sports Medicine, National Strength and Conditioning Association, USA Weightlifting, and CrossFit, and is a former Starting Strength coach and staff member. He has coached individuals worldwide for over a decade. As a competitive powerlifter, his best lifts include a 640lb squat, 430lb bench press, 275lb overhead press, and 725lb deadlift at a bodyweight of 198lb.
Austin Baraki, MD
Austin Baraki is a practicing Internal Medicine physician, competitive lifter, and strength coach based in San Antonio, Texas. He completed his undergraduate degree in Chemistry at the College of William & Mary, his medical degree at Eastern Virginia Medical School, and Internal Medicine residency at the University of Texas Health Science Center in San Antonio.
